In-Vitro Diagnostics Quality Control Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global In-Vitro Diagnostics Quality Control Market Trends and Insights

Growing Global Disease Burden

Chronic and infectious diseases are expanding test volumes that need daily quality oversight, driving direct growth in the in-vitro diagnostics quality control market. Non-communicable ailments accounted for 74% of global deaths in 2024, and rising diabetes prevalence boosts demand for glycated hemoglobin controls that laboratories must run at multiple levels each day. Oncology laboratories increased liquid biopsy volumes by 28% in 2025, yet fewer than 40% stock circulating tumor DNA materials with defined allele frequencies, leaving a compliance gap regulators have begun to question^{[1]U.S. National Cancer Institute, “Liquid Biopsy Market Trends 2025,” National Cancer Institute, cancer.gov}. Public health facilities in Brazil and Thailand tripled molecular control inventories during 2024-2025 outbreaks, underscoring how epidemiological swings escalate per-test quality costs. Quality spending now aligns more with disease volatility than routine growth, favoring vendors that can scale multi-analyte reference kits quickly. This trend will keep upward pressure on consumable demand even as laboratories adopt data platforms.

Expansion of Accredited Clinical Laboratories

Accreditation has shifted quality control from optional to mandatory spending, enlarging the in-vitro diagnostics quality control market across mature regions. The College of American Pathologists counted 8,200 accredited U.S. labs by December 2025, a 6% rise since 2023, after Medicare tied reimbursement eligibility to deemed-status recognition. ISO 15189 became a prerequisite for public procurement in Germany and France, prompting 1,400 private labs to launch compliance programs that require documented controls on every platform. China ordered all tertiary hospitals to secure ISO 15189 status by 2027, influencing roughly 3,000 facilities and fueling short-term spikes in bulk control purchases. Accreditation also pushes buyers toward suppliers that can provide certificates traceable to international reference methods, consolidating share among multinational vendors. Laboratories now treat control documentation as a credential for payer negotiations and public tenders.

Technological Advancements in IVD Platforms

High-throughput systems such as Roche cobas pro process up to 300 samples per hour and require controls with proven commutability with fresh human serum, a feature that only a few third-party suppliers offer today. Abbott Alinity flagged 12% of generic controls as out of linearity during 2025 validations, pressuring labs to adopt proprietary materials or finance costly bridging studies. In molecular diagnostics, next-generation sequencing panels require synthetic DNA references with single-nucleotide precision, yet fewer than eight suppliers hold FDA clearance for BRCA1 or EGFR materials. Specialty firms now develop modular kits that laboratories can tailor for custom gene lists, opening new revenue lanes. Platform vendors have begun bundling exclusive controls within reagent-rental contracts to lock in service revenue. This technical escalator elevates entry barriers and steers demand toward integrated ecosystems.

Shift Toward Decentralized and Point-of-Care Testing

Point-of-care expansion fragments oversight and exposes quality gaps, affecting near-term growth of the in-vitro diagnostics quality control market. The FDA cleared 47 new POCT devices in 2025, but only 18% included stability data for tropical field conditions, leaving clinics uncertain about control frequency. A 2024 CLIA audit found that 34% of physician office labs skipped external control runs due to cost and workflow concerns. Suppliers responded with single-use ambient-stable formats that remove refrigeration needs and cut waste in low-volume sites. Device makers are also embedding electronic algorithms that validate performance using patient result patterns, a shift that could erode up to 20% of traditional control demand by 2030 if regulators approve the method. The tension between convenience and traceability will determine adoption curves.

Unfavorable Reimbursement Landscape

Payment cuts force laboratories to ration control use, weighing on near-term growth of the in-vitro diagnostics quality control market. Medicare’s schedule has reduced test fees by a cumulative 8.5% since 2021 and more reductions are scheduled through 2027, prompting 42% of U.S. hospital labs to move from twice-daily to once-daily runs for stable analytes in 2025 surveys. Commercial insurers introduced prior authorization on molecular tests, shrinking volumes by 18% and delaying purchases of high-cost next-generation sequencing controls. German statutory payers negotiated a 3.2% tariff cut in 2025 that hit small independent labs hardest, as they lack the volume discounts enjoyed by national chains^{[2]GKV-Spitzenverband, “Laboratory Tariff Agreement 2025,” GKV-Spitzenverband, gkv-spitzenverband.de}. Consolidation accelerated, with 127 U.S. independents acquired in 2025 because shrinking margins made standalone quality programs unsustainable. Suppliers face pressure to lower per-test costs or risk being replaced by in-house electronic quality schemes.

Limited Laboratory Infrastructure in Emerging Regions

Power outages and weak cold-chain capacity limit product viability and sales potential in many low-income markets, restraining the long-term trajectory of the in-vitro diagnostics quality control market. Only 29% of sub-Saharan African labs reported uninterrupted electricity in a 2024 WHO audit, and fewer than 15% possessed functional refrigeration for temperature-sensitive controls. A 2025 survey in India found that 61% of district labs lacked staff trained to interpret Westgard rules, leading to undetected systematic errors. Import tariffs ranging from 12% in Vietnam to 28% in Nigeria inflate control costs by up to 50%, pushing buyers toward uncertified local products with erratic lot performance^{[3]World Bank, “Customs Tariffs on Medical Reagents Database 2025,” World Bank, worldbank.org}. Regulatory bodies in fewer than 20 African and Southeast Asian countries mandate external quality assessment, removing incentives to invest in premium controls. Until multilateral funding improves infrastructure, growth in these regions will lag the global average.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Products & Services: Data Platforms Reshape Value Capture

Quality control products accounted for 71.32% of 2025 revenue, equal to about two-thirds of the in-vitro diagnostics quality control market, reflecting laboratories’ continuing need for multi-level liquid and lyophilized reagents for daily instrument checks. Data management solutions, although still a smaller slice, are expanding at a 6.75% CAGR as laboratories adopt cloud platforms that automate Westgard rule application and flag instrument drift in real time. Roche’s navify Quality Control Management demonstrated a 19% cut in unplanned downtime across 34 hospitals by triaging service calls before errors reached patients. Bio-Rad broadened its Liquichek line to 42 analytes per vial, lowering inventory complexity and sustaining reagent demand. At the same time, subscription analytics generate recurring revenue that offsets slowing vial growth.

Laboratories now evaluate suppliers on the combined value of reagents, middleware, and proficiency testing programs, a shift that re-orders procurement criteria toward end-to-end ecosystems. As a result, data platforms win share even when offered at premium prices because they quantify cost avoidance from prevented errors. The in-vitro diagnostics quality control market share for pure-play software is poised to rise as younger lab directors prioritize workflow efficiency over per-vial cost. Suppliers that cannot complement reagents with predictive analytics risk being relegated to second-tier status. Demand therefore tilts toward companies owning ISO-17025 plants plus software development teams, giving multinationals a scale edge.

By Application: Molecular Diagnostics Outpaces Legacy Segments

Immunochemistry retained 31.12% of 2025 demand, benefiting from thyroid, cardiac, and tumor marker panels that require daily multi-level controls. Yet molecular diagnostics is growing at 6.87% as oncology companion tests and infectious-disease panels migrate to multi-gene workflows that need synthetic DNA references traceable to WHO standards. Coagulation is another bright spot because direct oral anticoagulants force laboratories to validate anti-Xa assays with chromogenic substrates, raising control spend per test by about 12% since 2024. Clinical chemistry and hematology remain mature but stable, underpinned by high-volume metabolic panels.

The in-vitro diagnostics quality control market for molecular assays will grow as next-generation sequencing panels expand from single-gene panels to 500-plus-gene oncology portfolios. Fewer than eight vendors now hold FDA clearance for BRCA or EGFR reference materials, creating scarcity pricing and high gross margins. Point-of-care testing controls are also rising because the U.S. FDA draft guidance now expects stability data under worst-case tropical environments, spurring adoption of ambient-stable lyophilized kits. Suppliers that tailor modular kits enabling laboratories to customize mutation mixes stand to capture incremental share. Those lacking nucleic-acid manufacturing capacity face a steep entry barrier, reinforcing consolidation trends in advanced applications.

By End User: IVD Manufacturers Internalize Quality Functions

Independent clinical laboratories generated 44.55% of 2025 revenue, reflecting routine chemistry, immunoassay, and hematology workloads that depend on twice-daily control runs. Hospitals follow, but their growth is tempered as group purchasing organizations negotiate multi-year contracts that cap price increases at 2-3% annually. IVD manufacturers and contract research organizations, though smaller, are expanding at a 7.86% CAGR by conducting in-house validation to shorten regulatory timelines and secure design-history files before product launch. Academic centers buy specialized controls for translational research, driven by the U.S. NIH rigor guidelines that require assay validation evidence in every omics grant.

The in-vitro diagnostics quality control market share for manufacturer-run labs will climb as platform vendors vertically integrate lot-release testing and proficiency programs. Ambulatory and physician-office laboratories lag because 34% failed to meet recommended control frequencies during the 2025 CLIA reviews, citing workflow disruptions. Suppliers responded with single-use vials that cut handling time by 60%, narrowing the compliance gap. Over the forecast period, purchasing power will continue to shift toward multinational IVD companies and consolidated hospital networks, nudging smaller independent labs either to merge or to outsource quality functions.

Geography Analysis

North America captured 44.12% of 2025 revenue, underpinned by stringent CAP accreditation and CMS payment rules that reward documented quality, but growth now moderates as reimbursement cuts pressure laboratories to reduce daily control frequency. The United States alone accounts for more than three-quarters of regional spending, yet its cost-containment climate is pushing suppliers to offer value-based contracts that tie price to instrument uptime. Canada shows steadier momentum because provincial health plans have ring-fenced laboratory budgets through 2028.

Europe is the second-largest region, driven by Germany, France, and the United Kingdom, which together contributed roughly 62% of 2025 sales after the EU IVDR mandated lot-to-lot surveillance for every control shipment. Laboratories fast-tracked ISO 15189 certification to qualify for public tenders, adding about 1,400 new accredited sites in 2024-2025. Southern Europe lags due to fragmented payer systems, but convergence toward Northern standards is expected by 2028. The in-vitro diagnostics quality control market size tied to European public hospitals will likely edge higher as digital quality records become compulsory.

Asia-Pacific advances at a 5.65% CAGR through 2031, led by China’s mandate that all tertiary hospitals secure ISO 15189 status by 2027, a move that touches about 3,000 institutions. India’s private chains continue rolling out tier-2 city labs, broadening reach where facility density is under one lab per 100,000 people. Japan and South Korea remain mature but demand premium multi-level controls as ministries enforce daily QC logs. Emerging ASEAN markets wrestle with refrigeration gaps, so ambient-stable kits dominate orders. The Middle East and Africa still represent a small share, yet Gulf Cooperation Council spending on reference labs positions the region for mid-single-digit growth. South America’s outlook hinges on Brazil and Argentina, where currency swings hinder capital equipment buys but keep consumable purchases resilient, anchoring a baseline for the in-vitro diagnostics quality control market share in the region.

Regulatory Landscape

Regulation is tightening around documented, traceable quality systems for IVD manufacturing and laboratory operations, which is increasing the importance of third-party and instrument-integrated QC materials. In the United States, the FDA Quality Management System Regulation (QMSR) became effective in February 2026 and incorporates ISO 13485:2016 by reference, reinforcing end-to-end controls, documentation, and supplier quality management practices that flow through to QC design, labeling, and lot release.

In Europe, the IVDR framework continues to formalize conformity assessment processes and reduce uncertainty around Notified Body operations. In May 2026, Commission Implementing Regulation (EU) 2026/977 set uniform operational rules and defined maximum timelines for certain notified body activities (including a 90-day QMS review timeline), while the IVDR harmonised standards list was updated in June 2026 via Commission Implementing Decision (EU) 2026/1313 (including EN ISO 15223-1:2021/A1:2025). Separately, the FDA LDT final rule published in May 2024 phases out broad enforcement discretion for laboratory developed tests over four years, increasing the compliance burden on clinical laboratories and intensifying demand for validated QC and traceable documentation.

Value Chain Analysis

The value chain spans (1) upstream inputs such as human-source matrices (including plasma collection networks), synthetic polymer feedstocks, preservatives, and packaging; (2) specialized reference material and control manufacturers producing liquid and lyophilized multi-analyte controls and synthetic nucleic-acid materials; (3) IVD system providers and diagnostics specialists that bundle proprietary controls, software, and service; and (4) distribution through direct contracting with hospital networks and consolidated independent laboratories, plus established diagnostic distributors supporting hospital and point-of-care sites. Data-layer participants (middleware and cloud QC management) increasingly sit between controls and end users by converting QC runs into audit-ready documentation and performance dashboards.

Bottlenecks and value capture are shaped by certified reference material lead times, scarcity of high-titre or rare biological materials that constrain disease-state matrices, and regulatory throughput limits such as EU Notified Body capacity. Policy shifts also affect sourcing and localization decisions: the EU amendment 2024/1860 revised IVDR transitional provisions for legacy devices, and the US FDA May 2024 final rule on LDTs increases QMS requirements that pull documentation upstream to suppliers. Tariff pressure on outside-the-US manufactured medical device components and reagents adds another cost variable, which is accelerating interest in localized manufacturing, synthetic materials where feasible, and tighter supplier qualification to maintain lot-to-lot consistency.

Market Opportunities and Future Outlook

A major opportunity area sits at the intersection of regulation and laboratory workflow digitization, where laboratories and IVD vendors are standardizing QC documentation to satisfy audits, reimbursement-linked quality requirements, and cross-site comparability. ISO 15189:2022 is used as a benchmark for medical laboratory quality management in many accreditation programs and is referenced in IVDR-related discussions for laboratories running tests under Article 5(5), creating whitespace for vendors that can package ISO-traceable controls together with automated rule application, corrective action documentation, and connectivity into LIS and broader quality systems. The market also shows room for multi-analyte and molecular reference materials that traditional controls cannot support, particularly for NGS and liquid-biopsy workflows where defined allele frequency materials and commutability expectations raise the technical bar.

Connected QC and remote monitoring platforms also represent a nearer-term opportunity as laboratories shift from manual, episodic checks to continuous performance oversight across instrument fleets and decentralized sites. Within the current market context, middleware integration has demonstrated measurable reductions in reportable errors in hospital pilots during 2025, which supports broader adoption of QC data management as a procurement criterion rather than an add-on. Point-of-care expansion and environmental stability requirements further highlight demand for ambient-stable, single-use controls and for systems that embed QC into instrument software to reduce operator burden while preserving traceability under evolving US and EU compliance expectations.